LNCARSR and renal cell carcinoma: Unfortunately, up to 20% of patients with RCC show an intrinsic resistance to sunitinib, and most of the other patients develop resistance during the course of therapy.55 Qu et al. used in vitro and in vivo screening algorithms to discover new pathways associated with sunitinib resistance.56 They observed that a previously uncharacterized lncRNA, lncARSR (lncRNA activated in RCC with sunitinib resistance), is upregulated after resistance development.